Agenus Inc (AGEN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown positive price movement recently, the financial performance is weak, with significant declines in net income and EPS. Additionally, there are no strong trading signals or positive catalysts to justify immediate investment. Holding off for now is recommended.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. RSI is at 73.259, suggesting the stock is nearing overbought territory but still neutral. Moving averages are converging, showing no clear trend. Key resistance levels are at 3.315 and 3.461, with support at 2.841 and 2.695. Overall, the technical indicators suggest mild bullishness but no strong entry signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market. However, the overall volume and open interest are relatively low, limiting the reliability of this data.

Technical Summary

Sell

Buy

Positive Catalysts

The stock price has shown a recent increase of 4.02% in the regular market and 0.45% post-market. Revenue grew by 20.40% YoY in the latest quarter, which is a positive sign.

Neutral/Negative Catalysts

Net income dropped significantly by -196.12% YoY, and EPS declined by -162.99% YoY. Gross margin also slightly decreased. No recent news, analyst ratings, or significant insider/hedge fund activity to support a bullish case. No recent congress trading data.

Financial Performance

In Q3 2025, revenue increased by 20.40% YoY to $30.24M. However, net income dropped by -196.12% YoY to -$63.86M, and EPS fell by -162.99% YoY to 1.94. Gross margin slightly declined to 97.88%. Overall, financial performance is weak despite revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for evaluation.

1 Analyst Rating

Wall Street analysts forecast AGEN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.340

Low

Averages

High

Current: 3.340

Low

Averages

High

H.C. Wainwright

Neutral -> Buy

upgrade

$25

AI Analysis

2025-06-04

Reason

H.C. Wainwright

Price Target

$25

AI Analysis

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.

Baird

Neutral

maintain

$4 -> $6

2025-06-04

Reason

Baird

Price Target

$4 -> $6

2025-06-04

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AGEN

Unlock Now

AGEN Should I Buy

AGEN Should I Buy

Should You Buy Agenus Inc (AGEN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch